Neuropathic Pain in a Cancer Patient Responding to Subcutaneously Administered Lignocaine

Devulder, Jacques; Ghys, Liesbet; Dhondt, W; Rolly, G

doi:10.1097/00002508-199309000-00011

Cited by 22 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The latter would be preferred in continuous infusion over days to weeks, compared to slow bolus over minutes to hours. 7 , 35 , 36 It is anticipated to be safer and more feasible maintaining a SC line for long periods outside the hospital, especially within the home setting. 5 , 15 Moderate diversity is noted in drug administration schedules, indicating a lack of consensus.…”

Section: Discussionmentioning

confidence: 99%

Parenteral Lidocaine for Complex Cancer Pain in the Home or Inpatient Hospice Setting: A Review and Synthesis of the Evidence

Chong¹,

Yeo²

2021

Journal of Palliative Medicine

View full text Add to dashboard Cite

Background: Cancer pain can remain refractory despite escalating opioids and adjuvants. Systemic Lidocaine is an option, but current approaches are hospital centered. While advantageous in advanced cancer, evidence is lacking for parenteral Lidocaine use in community-based care. Objectives: Review evidence for parenteral lidocaine in complex cancer pain outside the hospital setting. Design: Systematic review of peer-reviewed articles of any study design, including reviews. Search in four databases used keyword variations of “cancer,” “pain,” “Lidocaine,” and “parenteral.” Search was extended through reference lists of full texts assessed. Abstracted data from articles screened and selected were synthesized narratively by a palliative care clinician in Singapore. Results: Eight hundred eighty-three articles identified were screened by title and abstract. Twenty-eight full texts were assessed. Seven articles fulfilled criteria for synthesis of findings. A total of 73 patients received parenteral Lidocaine for mixed pains, reported collectively in 1 retrospective chart review, 3 practice guidelines, 2 case series, and 1 case study. Intravenous or subcutaneous Lidocaine was commenced in hospital or hospice and continued at home. Dosages and administration schedules varied, involving slow bolus with continuous infusion or the latter alone, for up to 240 days. All produced positive outcomes, with no severe adverse events. Monitoring included routine vital signs and conscious levels; electrocardiogram, liver, and renal function tests were uncommon. Lidocaine levels were not consistently assessed. Conclusion: Parenteral Lidocaine can be effective and safe in the community setting. More empirical studies are needed to inform patient selection and treatment protocol, and to validate expected outcomes.

show abstract